2023年第46届圣安东尼奥乳腺癌研讨会（San Antonio Breast Cancer Symposium，SABCS）将于12月5日至9日在美国得克萨斯州圣安东尼奥举行。该会议汇聚了全球约1万名临床医生和专家，是规模最大、最具影响力的乳腺癌研究盛会。
日前，大会公布了本次会议的详细日程及研究题目。【肿瘤资讯】从官网获得现有资讯，将LBA Oral Session、General Session、Rapid Fire Session所有口头报告研究整理如下，以飨读者。
LBA专场
Late Breaking Abstracts Oral Session
地点和时间：Star at Night Ballroom 1-2, 12月8日12:00 pm - 12:45 pm（Central Time）（本文均为美国中央时间）
LBO1-01 3期KEYNOTE-522研究：新辅助帕博利珠单抗或安慰剂+化疗后辅助帕博利珠单抗或安慰剂治疗早期TNBC的无事件生存期（EFS）数据更新
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
讲者：Peter Schmid, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, United Kingdom
LBO1-02 APTneo Michelangelo研究：加或不加阿替利珠单抗新辅助治疗HER2+早期高危和局晚期乳腺癌病理完全缓解（pCR）的疗效
Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial
讲者：Luca Gianni, Fondazione Michelangelo, Milan, Italy
LBO1-03 BCT1902/IBCSG 61-20 Neo-N研究：新辅助纳武利尤单抗（N）单药治疗（2周），之后接受N+卡铂+紫杉醇（CbP）（12周）vs 同时接受N+CbP治疗TNBC的Ⅱ期随机研究
Randomized Phase II Study of Neoadjuvant Nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Negative Breast Cancer (TNBC): (BCT1902/IBCSG 61-20 Neo-N)
讲者：Sherene Loi, Peter McCallum Cancer Centre, Melbourne, Australia
LBO1-04 Zanidatamab+哌柏西利+氟维司群治疗HER2+/HR+转移性乳腺癌的Ⅱa期研究主要结果
Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)
讲者：Santiago Escrivá-de-Romani, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain
LBO1-05 ADAPTcycle试验：年龄和卵巢功能抑制(OFS)对短期术前内分泌治疗的内分泌应答的影响（n=4334）
Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334
讲者：Oleg Gluz, West German Study Group, Moenchengladbach, Germany; Breast Center Niederrhein, Ev. Hospital Bethesda, Moenchengladbach, Germany
全体大会 1
General Session 1
地点和时间：Hall 1，12月6日 9:00 am - 12:00 pm
GS01-01 CheckMate 7FL研究探索性分析：新辅助化疗±纳武利尤单抗治疗高危ER+/HER2-原发性乳腺癌后的生物标志物结果
Biomarker results in high-risk estrogen receptor positive, human epidermal growth factor receptor 2 negative primary breast cancer following neoadjuvant chemotherapy ± nivolumab: An exploratory analysis of CheckMate 7FL
讲者：Sherene Loi, Peter McCallum Cancer Centre, Melbourne, Australia
GS01-02 Ⅲ期KEYNOTE-756研究：帕博利珠单抗或安慰剂+化疗新辅助治疗，序贯帕博利珠单抗或安慰剂+内分泌疗法辅助治疗高危、早期ER+/HER2-乳腺癌
Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756
讲者：Aditya Bardia, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
GS01-03 ALEXANDRA/IMpassion030 Ⅲ期试验中期分析：Ⅱ期和Ⅲ期TNBC辅助化疗加用阿替利珠单抗可能无法改善疗效
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
讲者：Michail Ignatiadis, Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium
GS01-04 Discussant for GS01-01, GS01-02, and GS01-03
Laura Huppert, University of California, San Francisco
GS01-05 随机、开放标签、Ⅱ期KEYLYNK-009研究：帕博利珠单抗+化疗诱导治疗后，帕博利珠单抗+奥拉帕利 vs 帕博利珠单抗+化疗治疗局部复发不可手术或转移性TNBC
Pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: Randomized open-label phase 2 KEYLYNK-009 study
讲者：Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
GS01-06 特定良性乳腺疾病诊断与未来乳腺癌风险关联的进一步证据
Advancing evidence of the associations between specific benign breast diagnoses and future breast cancer risk
讲者：Olivia Sattayapiwat, University of California at Davis, Davis, California
GS01-07 Discussant for GS01-06
Anne Marie McCarthy, University of Pennsylvania
GS01-08 CDK4/6抑制是NF1缺失ER+乳腺癌的潜在易损性
CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer
讲者：Eric Chang, Lester Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
GS01-09 Discussant for GS01-08
Shom Goel, The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
GS01-10 HER2CLIMB-02：妥卡替尼和恩美曲妥珠单抗用于经治HER2阳性转移性乳腺癌的随机、双盲、3期试验
HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer
讲者：Sara Hurvitz, Fred Hutchinson Cancer Center/University of Washington, Seattle, Washington
全体大会 2
General Session 2
地点和时间：Hall 1，12月7日 8:15 am - 11:15 am
GS02-01 Datopotamab deruxtecan对比化疗治疗无法手术或转移性ER+/HER2-乳腺癌患者：随机3期TROPION-Breast01研究的疗效、安全性和生物标志物结果
Randomised phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01.
讲者：Aditya Bardia, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
GS02-02 OPBC05/EUBREAST-14R/ICARO研究：新辅助化疗后的淋巴结孤立肿瘤细胞（ITCs）是腋窝清扫的指征吗？
Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
讲者：Giacomo Montagna, Memorial Sloan Kettering Cancer Center, New York, New York
GS02-03 Discussant for GS02-02
Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston, Massachusetts
GS02-04 BRCA1突变乳腺癌女性的手术治疗：双侧乳房切除术对生存影响的国际分析
Surgical treatment of women with breast cancer and a BRCA1 mutation: an international analysis of the impact of bilateral mastectomy on survival
讲者：Kelly Metcalfe, University of Toronto, Toronto, Ontario, Canada
GS02-05 早期乳腺癌腋窝治疗概述：对29项随机试验中20273名女性长期结局的患者水平荟萃分析
Overview of axillary treatment in early breast cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials
讲者：Gurdeep S. Mannu, University of Oxford, Oxford, England
GS02-06 国际随机SENOMAC试验的首批结果：未进行腋窝淋巴结清扫的前哨淋巴结阳性乳腺癌的无复发生存
Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial
讲者：Jana de Boniface, Karolinska Institutet, Stockholm, Sweden;Capio St. Göran’s Hospital, Stockholm, Sweden
GS02-07 NRG Oncology/NSABP B-51/RTOG 1304研究的主要结果：对经活检证实腋窝淋巴结受累且新辅助化疗后病理淋巴结阴性的患者进行局部区域照射
Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304
讲者：Eleftherios Mamounas, Orlando Health Cancer Institute, Orlando, Florida
GS02-08 IDEA试验五年结果：针对50-69岁、经基因组学筛选有利的Ⅰ期乳腺癌绝经后患者，在保乳手术后行内分泌治疗而未放疗的疗效
Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer
讲者：Reshma Jagsi, Emory University, Atlanta, Georgia
GS02-09 Discussant for GS02-06, GS02-07, and GS02-08
Andrea V. Barrio, Memorial Sloan Kettering Cancer Center, New York, New York
GS02-10 结构化和个体化运动计划对转移性乳腺癌患者疲劳和健康相关生活质量的影响：PREFERABLE-EFFECT国际随机对照研究
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
讲者：Anne M. May, University Medical Center, Utrecht, Netherlands
GS02-11 乳腺癌患者中断内分泌治疗后尝试妊娠的生育能力保护和辅助生殖技术（ART）
Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
讲者：Hatem A. Azim, Jr., Monterrey Institute of Technology, Monterrey, Mexico
全体大会 3
General Session 3
地点和时间：Hall 1，12月8日8:15 am - 11:15 am
GS03-01 磁共振成像和12基因表达测定以优化乳腺导管原位癌局部治疗：E4112研究5年临床结果
Magnetic Resonance Imaging and a 12-gene expression assay to optimize local therapy for ductal carcinoma in situ: 5-year clinical outcomes of E4112
讲者：Seema Khan, Northwestern University, Evanston, Illinois
GS03-02 Mammo-50非劣效性试验：≥50岁早期乳腺癌患者进行乳腺X线摄影监测，对比每年一次与低频率乳腺X线摄影监测的结果
Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
讲者：Janet A. Dunn, University of Warwick, Coventry, England
GS03-03 瑞波西利+非甾体芳香化酶抑制剂（NSAI）辅助治疗HR+/HER2-早期乳腺癌患者：NATALEE试验的最终无浸润性疾病生存（iDFS）分析
Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial
讲者：Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, Texas
GS03-04 人工智能结合基因组学揭示乳腺浸润性小叶癌CDH1失活的新机制
Novel mechanisms of CDH1 inactivation in breast invasive lobular carcinoma unveiled by the integration of artificial intelligence and genomics
讲者：Fresia Pareja, Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
GS03-05 Discussant for GS03-04
Frederick M. Howard, University of Chicago, Chicago, Illinois
GS03-06 monarchE试验：HR+、HER2-、淋巴结阳性高危早期乳腺癌患者原发肿瘤的基因组和转录组学分析
Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
讲者：Nicholas C. Turner, Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
GS03-07 PALLAS（AFT-05）辅助试验中方案定义的生物标志物分析：从HR+/HER2-早期乳腺癌RNA测序的基因组亚型
Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer
讲者：Daniel Stover, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
GS03-08 Discussant for GS03-07
Christos Sotiriou, Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium
GS03-09 转移性乳腺癌中融合RNAs的特征和治疗探索
Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers
讲者：Nolan Priedigkeit, Dana-Farber Cancer Institute / Broad Institute of MIT and Harvard, Boston, Massachusetts
GS03-10 PI3K-α变构抑制克服继发性PIK3CA突变介导的对正构抑制剂的靶点依赖性耐药
Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations
讲者：Andreas Varkaris, Massachusetts General Hospital, Boston, Massachusetts
GS03-11 胚系介导的免疫编辑塑造乳腺癌亚型和转移倾向
Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity
讲者：Christina Curtis, Stanford University, Stanford, California
GS03-12 新辅助化疗和HER2靶向治疗后辅助ado-trastuzumab emtansine 与曲妥珠单抗治疗残留浸润性HER2阳性早期乳腺癌的Ⅲ期研究：KATHERINE最终 IDFS 和更新的 OS 分析
Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis
讲者：Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany
快速讨论环节1: 迷你口头报告
Rapid Fire Session 1: Mini-Oral Presentations
地点和时间：Hall 1，12月6日12:15 pm - 1:00 pm
RF01-01 SERENA-3：一项评估ER+/HER2-绝经后原发性乳腺癌患者camizestrant治疗剂量和持续时间的随机术前机会窗口研究
SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer
讲者：John Robertson, University of Nottingham, Nottingham, United Kingdom; University Hospitals of Derby and Burton, Derby, United Kingdom
RF01-02 一项在计划行乳房切除术的女性中使用endoxifen透皮制剂的随机I期术前窗口试验：皮肤安全性、乳腺内药物分布和生物效应的评估
A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: evaluation of dermal safety, intra-mammary drug distribution, and biologic effects
讲者：Oukseub Lee, Northwestern University, Chicago, Illinois
RF01-03 PARSIFAL-LONG：对PARSIFAL研究中接受氟维司群+哌柏西利 vs 来曲唑+哌柏西利治疗的HR+/HER2-晚期乳腺癌患者的延长随访
PARSIFAL-LONG: Extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study
讲者：Antonio Llombart-Cussac, Hospital Arnau de Vilanova, Valencia, Spain
RF01-04 Ⅱ期开放标签 FOENIX-MBC2研究的最终结果：futibatinib用于携带高水平FGFR1基因扩增的局部晚期/转移性HR+/HER2-乳腺癌成年患者的疗效和安全性
Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification
讲者：Senthil Damodaran, The University of Texas MD Anderson Cancer Center, Houston, Texas
RF01-05 PARPi耐药BRCA1/2突变乳腺癌中RAD51 foci和复制叉动力学的功能评估
Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer
讲者：Elizabeth Harvey-Jones, King's College London Great, Maze Pond, United Kingdom
RF01-06 特瑞普利单抗联合节拍化疗治疗HER2-转移性乳腺癌的疗效和安全性：一项基于自适应贝叶斯随机设计的多中心II期研究
Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer: a multicenter phase II trial based on a Bayesian adaptive randomized design
讲者：莫红楠 中国医学科学院肿瘤医院
RF01-07 Tinengotinib治疗晚期或转移性HR+/HER2-乳腺癌或TNBC患者的疗效和安全性
The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2- breast cancer or TNBC
讲者：Piha-Paul Sarina, The University of Texas MD Anderson Cancer Center Houston, Texas
RF01-08 一项评估低剂量 vs 标准剂量奥氮平联合三联止吐疗法预防实体瘤患者高致吐性化疗引起的恶心和呕吐的随机、开放标签Ⅲ期试验（OLAnzaPiNE）
A randomized, open-label phase III trial evaluating low-dose vs standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy- induced nausea and vomiting in solid tumors (OLAnzaPiNE)
讲者：Jyoti Bajpai, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India
快速讨论环节2: 迷你口头报告
Rapid Fire Session 2: Mini-Oral Presentations
地点和时间：Hall 1，12月7日 12:00 pm - 12:45 pm
RF02-01 阿那曲唑、哌柏西利、曲妥珠单抗和帕妥珠单抗治疗HR+/HER2+转移性乳腺癌的多中心、Ⅰ/Ⅱ期试验 (ASPIRE)
A multicenter, phase i/ii trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (hr)-positive, HER2-positive metastatic breast cancer (ASPIRE)
讲者：Amy Tiersten, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York
RF02-02 BBO-10203，一种首创的口服生物可利用的选择性共价小分子，可在不影响葡萄糖代谢的情况下可抑制RAS驱动的PI3Kα活性
BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kα activity without affecting glucose metabolism
讲者：Pedro Beltran, BridgeBio Pharma Oncology Therapeutics, Orinda, California
RF02-03 DESTINY-Breast08（一项Ⅰb期、开放标签、多中心、剂量扩展研究）：德曲妥珠单抗（T-DXd）联合阿那曲唑或氟维司群治疗HER2低表达、HR+晚期/转移性癌症患者
Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08)
讲者：Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York
RF02-04 JCOG1607 HERB TEA研究：一项比较恩美曲妥珠单抗与曲妥珠单抗、帕妥珠单抗和多西他赛治疗转移性HER2阳性乳腺癌老年患者的Ⅲ期研究
A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with metastatic HER2-positive breast cancer (JCOG1607 HERB TEA study)
讲者：Akihiko Shimomura, National Center for Global Health and Medicine, Tokyo, Japan
RF02-05 评估BB-1701用于局部晚期/转移性HER2低表达乳腺癌患者的安全性、耐受性、药代动力学和抗肿瘤活性的Ⅰ期研究队列扩展报告
Report on cohort expansion of phase i study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2 low breast cancer
讲者：Pamela Munster, University of California San Francisco, San Francisco, California
RF02-06 AVIATOR/TBCRC045：评估长春瑞滨+曲妥珠单抗联合或不联合阿维鲁单抗±utomilumab治疗HER2+转移性乳腺癌患者的随机Ⅱ期研究（NCT03414658）
AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658)
讲者：Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts
RF02-07 代谢和免疫参数的过早调节预测早期TNBC患者对禁食模拟饮食加化疗的肿瘤反应
Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
讲者：Claudio Vernieri, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
排版编辑：肿瘤资讯-Paine
苏公网安备 32059002004080号
